METHODS: We conducted a systematic review of publications in PubMed/ MEDLINE, Web of Science, and Embase up to 15 April 2023. Studies were included if they followed the Clinical and Laboratory Standards Institute (CLSI) criteria for drug susceptibility testing (DST). Using a random effects model, we assessed the overall in vitro BDQ resistance rate in clinical isolates of MABS and MAC. Sources of heterogeneity were analysed using Cochran\'s Q and the I2 statistic. All analyses were performed using CMA V3.0.
RESULTS: A total of 24 publications (19 reports for MABS and 11 for MAC) were included. Using 1 µg/mL and 2 µg/mL as the breakpoint for BDQ resistance, the pooled rates of in vitro BDQ resistance in clinical isolates of MABS were found to be 1.8% (95% confidence interval [CI], 0.7-4.6%) and 1.7% (95% CI, 0.6-4.4%), respectively. In the case of MAC, the pooled rates were 1.7% (95% CI, 0.4-6.9%) and 1.6% (95% CI, 0.4-6.8%) for 1 µg/mL and 2 µg/mL, respectively.
CONCLUSIONS: This study reports the prevalence of BDQ resistance in clinical isolates of MABS and MAC. The findings suggest that BDQ holds potential as a repurposed drug for treating MABS and MAC infections.
方法:我们对PubMed/MEDLINE,WebofScience,和Embase至2023年4月15日。如果研究遵循临床和实验室标准研究所(CLSI)的药物敏感性测试(DST)标准,则将其纳入研究。使用随机效应模型,我们评估了MABS和MAC临床分离株的体外总BDQ耐药率.使用Cochran'sQ和I2统计量分析异质性的来源。所有分析均使用CMAV3.0进行。
结果:共纳入24篇出版物(19篇关于MABS的报告和11篇关于MAC的报告)。使用1μg/mL和2μg/mL作为BDQ抗性的断点,发现MABS临床分离株中体外BDQ耐药的合并率为1.8%(95%置信区间[CI],0.7-4.6%)和1.7%(95%CI,0.6-4.4%),分别。在MAC的情况下,1μg/mL和2μg/mL的合并率为1.7%(95%CI,0.4-6.9%)和1.6%(95%CI,0.4-6.8%),分别。
结论:本研究报告了临床分离株MABS和MAC对BDQ的耐药率。研究结果表明,BDQ具有作为治疗MABS和MAC感染的再用途药物的潜力。